Quantum BioPharma Ltd. is trading 8.3% down at $4.47 as selling pressure persists after its lead MS candidate, Lucid-MS, was placed on an FDA clinical hold.
- The stock has declined sharply from levels above $7.00 following the June 2, 2026, disclosure of the regulatory action and subsequent management changes.
- Market sentiment remains negative as investors continue to digest the impact of the clinical hold, with no new catalysts reported this morning to offset the downward trend.